Inefficacy Kills Late-Stage Trial of Revlimid in Prostate Cancer

Clinical Trials Advisor
A A
Celgene is stopping a Phase III trial of blockbuster myeloma drug Revlimid to treat castrate-resistant prostate cancer after the formulation failed to show benefit over placebo.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00